We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Sep 2022
  • Code : CMI5198
  • Industry : Pharmaceutical
  • Pages : 193
  • Formats :

Mometasone, also referred to as mometasone furoate, is a corticosteroid used to treat asthma, hay fever, and several skin problems. Instead of managing asthma attacks, mometasone furoate  is used primarily to prevent them. By inhibiting infection-fighting white blood cells (WBCs) from reaching the affected area, it reduces inflammation, itching, and redness. Additionally, it inhibits the chemical messenger (histamine) that is accountable for body's allergic reactions. Symptoms of a variety of skin allergies as well as other allergic diseases like hay fever and allergic rhinitis are effectively treated by mometasone furoate.

Global Mometasone Furoate Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 596 million cases and 6.45 million deaths due to coronavirus (COVID-19) were reported till August 26, 2022, across the globe.

Impact of COVID-19 on Demand and Supply of Mometasone Furoate

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.

However, Coronavirus (COVID-19) pandemic is expected to positively impact growth of the global mometasone furoate market during the forecast period. For instance, according to an article published in International Immunopharmacology, a journal publishing articles in the areas of immunology, pharmacology, cytokine biology, etc., June 2021, a study was performed by University of Medical Sciences, Sari, Iran to check if mometasone furoate nasal spray is useful in the treatment of COVID-19 olfactory dysfunction patients.  The results showed that olfactory and taste dysfunctions brought on by the COVID-19 infection were significantly improved by using intranasal mometasone furoate spray without posing any risks.

Global mometasone furoate market is estimated to be valued at US$ 1,182.9 million in 2022, and is expected to exhibit a CAGR 7.4% over the forecast period (2022-2030).

Figure 1: Global Mometasone Furoate Market Share (%) Analysis, By Dosage Form, 2022

Mometasone Furoate  | Coherent Market Insights

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period.

Increasing research and development activities in formulation and development of mometasone furoate are expected to fuel growth of the global mometasone furoate market over the forecast period. For instance, according to a research article published in, Journal of Dermatological Treatment, March 2022, a study was conducted in India, the objective of the study was to develop an aspasomal mometasone furoate gel that is biologically active, delivers medication at a controlled rate, and requires minimal doses to treat psoriasis. Aspasomal gel with mometasone furoate was developed and it was found that, aspasomal gel with mometasone furoate   delivered the medication over a longer period of time and required fewer doses, expanding the scope of psoriasis treatment.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over forecast period.

Market players are engaged in product approvals, which is expected to boost the global mometasone furoate market growth over the forecast period. For instance, in March 2022, Perrigo Company plc, headquartered in Ireland, manufacturer of private label over-the-counter pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) approved its Nasonex 24HR Allergy (mometasone furoate) nasal spray, to treat symptoms of hay fever or other upper respiratory allergies such as nasal congestion, runny nose, sneezing, and itchy nose.

CMI table icon

Mometasone Furoate Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 1,104.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.4% 2030 Value Projection: US$ 2,099.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Dosage form: Nasal Spray, Cream, Ointment, Inhalers, Others (Topical Solutions, etc.)
  • By Indication: Inflammatory Skin Disorders, Asthma, Allergic rhinitis, Others (Hay Fever, etc.)
  • By Route of Administration: Nasal Administration, Topical, Oral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals

Growth Drivers:
  • Increasing research and development activities related to mometasone furoate
  • Increase in product approvals by market players
  • Increasing number of awareness campaigns by various organizations 
Restraints & Challenges:
  • Increasing side effects of mometasone furoate

Restraint- Global Mometasone Furoate Market

Side effects associated with the mometasone furoate are expected to hamper the growth of Global mometasone furoate over forecast period. The nasal spray form of mometasone may cause the following side effects:

  • headache
  • viral upper respiratory infections
  • sore throat
  • nose bleeds
  • cough
  • muscle and joint pain

Global Mometasone Furoate Market – Regional Analysis

On the basis of region, the global mometasone furoate market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the global mometasone furoate market, owing to increasing number of awareness campaigns by market players regarding psoriasis, as mometasone furoate is a drug used for the psoriasis treatment. For instance, on October 28 2020, Leo Pharma, a multinational pharmaceutical company, launched #everydaypsoriasis campaign, including a series of videos featuring patients that outline the everyday challenges of people living with psoriasis on World Psoriasis Day, October 28. The Leo Pharma campaign was held due to support of the annual International Federation of Psoriasis Associations (IFPA). Annual awareness day was dedicated to people living with psoriasis or psoriatic arthritis and was aimed at spreading information and raising the profile of these debilitating diseases.

Europe is expected to witness significant growth in the forecast period, owing to increasing approvals for mometasone furoate spray. For instance, in April 2019, The Ministry of Healthcare in Russia  granted Glenmark Pharmaceuticals Ltd., a research integrated global pharmaceutical company, permission to market Momate Rhino (Mometasone Furoate 50 mcg) metered nasal spray as an over-the-counter (OTC) medication for the treatment of seasonal and perennial allergic rhinitis in patients older than 18 years.

Figure 2: Global Mometasone Furoate Market Value (US$ Mn), by Region, 2022

Mometasone Furoate  | Coherent Market Insights

Global Mometasone Furoate Market – Competitive Landscape

Major players operating in the global mometasone furoate market include Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals.

Mometasone furoate topical is effective at reducing the redness, itching, swelling, and other pain caused by several skin conditions. Mometasone furoate is a corticosteroid drug also used to treat asthma and it is an effective treatment for a variety of skin allergies as well as other allergic conditions like hay fever and allergic rhinitis. 

Market Dynamics

Increasing prevalence of asthma worldwide is expected to witness significant growth in forecast period. For instance, according to the World Health Organization (WHO), in 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by asthma worldwide. Asthma is widely misdiagnosed and poorly managed, particularly in low- and middle-income countries. In most severe cases, asthma can be fatal.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over the forecast period. For instance, in April 2017, Amneal Pharmaceuticals LLC, a U.S.-based, publicly traded generics and specialty pharmaceutical company launched Mometasone furoate nasal spray, the first pharmaceutical product that Amneal Pharmaceuticals LLC had produced in spray form. Nasonex is therapeutic equivalent of mometasone furoate and is offered in 50 mcg/spray strength.

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period. For instance, according to an article published in Medicine, medical journal, in December 2019, a study was performed on patients with head and neck squamous cell carcinoma (HNSCC) to check efficacy of local application of mometasone furoate in reducing acute radiation dermatitis (ARD) in China. Patients were divided into two groups, test groups and control groups. The patients in test groups were given mometasone furoate once daily from the start of their radiotherapy until the test side skin acquired ARD lesions, and patients in control groups, were given no treatment at all. The study showed that, mometasone furoate inunction after high dose radiotherapy can prevent acute radiation dermatitis (ARD).

Key features of the study:

  • This report provides an in-depth analysis of the global mometasone furoate market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global mometasone furoate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include include Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
  • The global mometasone furoate market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mometasone furoate market

Detailed Segmentation:

  • Global Mometasone Furoate Market, By Dosage form:
    • Nasal Spray
    • Cream
    • Ointment
    • Inhalers
    • Others (Topical Solutions, etc.)
  • Global Mometasone Furoate Market, By Indication:
    • Inflammatory Skin Disorders
    • Asthma
    • Allergic rhinitis
    • Others (Hay Fever, etc.)
  • Global Mometasone Furoate Market, By Route of Administration:
    • Nasal Administration
    • Topical
    • Oral
  • Global Mometasone Furoate Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Mometasone Furoate Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Cipla *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Teva Pharmaceuticals
    • Glenmark Pharmaceuticals
    • AdvaCare Pharma
    • Medlab Pharmaceuticals Private Limited
    • Dermocare Laboratories
    • Iva Healthcare Private Limited
    • Unilab Chemicals & Pharmaceuticals Pvt Ltd
    • Organon group of companies
    • Cosette Pharmaceuticals
    • Taro Pharmaceutical Industries Ltd.
    • Hikma Pharmaceuticals.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global mometasone furoate market is expected to exhibit a CAGR of 7.4% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 1,182.9 Mn in 2022.
Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals are the prominent players operating in the market across the globe.
The market is expected to be valued at US$ 2,099.8 Mn in 2030.
North America is the prominent region in the market.
Increasing research and development activities in formulation and development of mometasone furoate by researchers, increase in product approvals, and increasing awareness campaigns about asthma and skin disorders by various organizations are some of the driving factors, which are expected to drive growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo